Author

admin

Browsing

xReality Group Limited (XRG) is pleased to announce it has been awarded a $5.6M AUD contract to deliver a new immersive training capability to the United States Department of Defence. The contract has been awarded to XRG by Acrolect Solutions LLC, DBA Endurance Group, who is serving as prime contractor to the US Department of Defence for the R&D effort.

The contract scope is to deliver a new immersive training capability and includes supplying Operator XR system licenses along with R&D services.The R&D project duration is 20 months commencing 11th September 2024.The contract presents opportunities for follow on work.

This project represents the first sale of Operator XR’s immersive training systems to a US Federal Government customer, and will be delivered across a period of 20 months starting 11th September 2024. The contract includes pathways for follow on work within the DoD and broader US Government agencies.

CEO of XRG, Wayne Jones said“the strategic importance of this project cannot be understated, representing Operator XR’s first major engagement with the US Department of Defence. Operator XR will be jointly developing a cutting edge capability that has the potential to expand into further global agencies as well as the many operational units within the US Defence Force.”

This ASX Release is authorised by the Board of xReality Group Limited.

Click here for the full ASX Release

This post appeared first on investingnews.com

Brightstar Resources Ltd (ASX: BTR) (Brightstar) is pleased to announce assay results from the inaugural Link Zone diamond drilling (DD) drilling program, part of the larger drilling program across the broader1.45Moz Au Brightstar portfolio in Menzies and Laverton. The program is targeting gold mineralisation for near-term development assessment of the Link Zone deposit, specifically targeting the Merriyulah and Golden Dicks deposits, located between the 287koz Au Lady Shenton System and 43koz Au Lady Harriet System at the Menzies Gold Project.

HIGHLIGHTS

Assays have been received for five diamond holes drilled at the Link Zone deposit at the Menzies Gold Project, part of the previously announced +30,000m drilling program1, with all holes at Link Zone drilled for metallurgical and geotechnical testwork purposesResults produced multiple high-grade intercepts targeting conceptual pit shells at the Merriyulah and Golden Dicks deposits within the Link Zone areaIntercepts returned at Link Zone include:LZMET24001:12.0m @ 11.90 g/t Au from 51.0m, including 1.0m @ 55.8g/t Au from 54.0m,10.0m @ 0.97 g/t Au from 23.0m, and0.6m @ 12.0g/t Au from 43.4mLZGT24001:1.0m @ 5.57 g/t Au from 45.0mLZGT24002:9.7m @ 1.77 g/t Au from 34.3mLZGT24003:8.49m @ 1.56 g/t Au from 14.0mLZGT24004:13.1m @ 1.19g/t Au from 11.3m

The program at Link Zone was focused within and adjacent to conceptual $3,000/oz Au pit shells, with holes targeting interpreted ore lode positions to gain mass for metallurgical testwork, along with varying orientations of geotechnical holes to gain information for assessment ahead of a potential small-scale mining campaign.

Brightstar’s Managing Director, Alex Rovira, commented“The diamond drilling component of our +30,000m campaign kicked off at Link Zone, with excellent grade results returned despite most holes being drilled for geotechnical purposes. Additionally, the metallurgical hole has given us valuable information for downhole lode grade variability, highlighted by a superb 6.0m @ 21.08g/t Au intercept containing six individual 1.0m +5.0 g/t Au intercepts within a broader down dip intercept of 12.0m @ 11.90g/t Au. We’re particularly encouraged by the grades returned, with these results released today along with our recently completed Link Zone RC program2 all returning grades well above the global MRE estimate for Link Zone emphasising areas for potential open pits.

Geotechnical logging was completed ahead of sampling & assaying, with the remaining core and existing RC samples being utilised for a metallurgical testwork program presently underway to feed into re-optimised pit shells and ultimately define a pathway to monetisation via a small-scale mining campaign similar to the successfully completed Selkirk Mining JV earlier this year.

Approximately 1km to the north, the Lady Shenton System RC drilling program will complete in the coming fortnight, with these results to be assessed and integrated into an updated Mineral Resource Estimate for the Definitive Feasibility Study presently underway. We look forward to updating the market with these results, along with previously completed RC and diamond programs at Jasper Hills and Second Fortune with assays progressing through the laboratory.”

TECHNICAL DISCUSSION

Five shallow diamond drill holes were completed at Link Zone (refer Figure 2), with holes drilled at varying orientations for metallurgical and geotechnical purposes. Three geotechnical holes were focused on drilling across the structure, with reported assays approximating true thicknesses and geometry of ore lodes; one geotechnical hole (LZGT24003) was drilled down dip targeting the west wall of the conceptual Merriyulah pit shell, whilst the single metallurgical hole (LZMET24001) was drilled down dip for sample mass purposes and thus should not be considered representative of lode thicknesses in the Golden Dicks deposit.

As shown in core photographs for LZGT24003 (Figure 4) and LZMET24001 (Figure 6), mineralisation observed at Link Zone is largely hosted by or along the margins of quartz-sulphide veins developed within shears associated with the Menzies Shear Zone, with the highest grades observed in intervals with abundant veining. The host rock is predominately amphibolitised basalt, with intermittent evidence of sulphide mineralisation (predominately pyrite) associated with shearing, bleaching and veining on geological contacts.

Click here for the full ASX Release

This post appeared first on investingnews.com

The pharmaceutical industry is the cornerstone of drug development, commercialization and marketing.

According to Statista, pharma sector revenues topped US$1 trillion for the first time in 2014, and have steadily increased since then to reach US$1.6 trillion in 2023. North America is the largest growth segment thanks to the behemoth US pharmaceutical industry. In terms of prescription drugs alone, Evaluate Pharma estimates that sales will reach US$1.7 trillion by 2030.

So which companies are responsible for the most growth and innovation in the pharma space?

1. Johnson & Johnson (NYSE:JNJ)

Company Profile

2023 revenue: US$85.16 billion

At the top of the list is pharmaceutical titan Johnson & Johnson, which is actively involved in research and development, as well as manufacturing and sales, for pharmaceuticals and medical devices. Last year, Johnson & Johnson spun off its consumer healthcare unit, which includes items for baby care, oral care, skin care and women’s health, into a new company named Kenvue.

In terms of pharmaceuticals, the company is focused on five major therapeutic areas: immunology, infectious diseases and vaccines, neuroscience, oncology ,and cardiovascular and metabolic diseases. It also manufactures over-the-counter pharmaceuticals.

Johnson & Johnson’s steady revenues year after year continue to place it at or near the top of the heap among the world’s biggest pharma companies. Sales of the pharma giant’s plaque psoriasis drug Tremfya grew by 18 percent year-over to reach US$3.15 billion in 2023. Johnson & Johnson’s oncology unit posted gains of 10.5 percent last year to reach US$17.66 billion.

Its blockbuster immunology drug Stelara also posted gains, growing from US$9.72 billion in sales in 2022 to US$10.86 billion in 2023. Looking forward, Fierce Pharma says Johnson & Johnson faces the challenge that it ‘has just one more year of reliable Stelara performance, as the drug is set to face biosimilars early next year.’

However, the company’s leadership expects to generate annual growth of 5 percent to 7 percent from 2025 to 2030, based on it having 10 or more drug products with the potential for peak sales of US$5 billion or higher.

2. Roche Holding (OTCQX:RHHBF,SWX:RO)

Company Profile

2023 revenue: US$65.32 billion

Headquartered in Basel, Switzerland, F. Hoffmann-La Roche, commonly known as Roche, operates two key divisions: pharmaceuticals and diagnostics. Roche Holding is its holding company.

Roche Diagnostics is made up of five key business areas: Roche Applied Science, Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics and Roche Tissue Diagnostics. The sectors Roche targets in its pharmaceutical division are as follows: hematology, oncology, neuroscience, infectious diseases, rare diseases, ophthalmology, respiratory, women’s health and inflammatory bowel diseases.

Although total reported revenues for Roche decreased by 7.2 percent from 2022 to 2023, the year-over-year decline was largely attributable to a stronger Swiss Frank over the US dollar. Still, the company managed to beat out Merck and Pfizer for second overall pharma company by revenue.

Fierce Pharma notes that Roche’s ‘star product’ in its portfolio is eye disease drug Vabysmo, which has proven a heavyweight challenger to Eylea, owned by Regeneron Pharmaceuticals (NASDAQ:REGN) and Bayer (OTC Pink:BAYZF,ETR:BAYN). Its second-largest selling drug is the hemophilia A therapy Hemlibra, which increased sales by 16 percent to US$4.6 billion i 2023.

3. Merck & Company (NYSE:MRK)

Company Profile

2023 revenue: US$60.1 billion

Merck & Company’s therapeutic areas include diabetes, cancer, multiple sclerosis and fertility. The conditions it aims to treat include cancer, HIV, HPV, Ebola, hepatitis C, cardio-metabolic disease and antibiotic-resistant infections.

Merck’s total revenues increased by a mere 1.4 percent in 2023, but it still managed to rise from fourth place to rank as the third top pharma company by revenue.

Last year, Merck’s checkpoint inhibitor Keytruda was the world’s biggest selling drug. ‘With FDA approvals to treat 16 types of advanced cancer, the drug pulled down US$25 billion globally in 2023, a 19 percent increase from the prior year,’ noted Fierce Pharma. This figure could reach US$30 billion by 2025.

However, Fierce Pharma is considered for what will happen when the drug’s patent expires in 2028, as it made up 41 percent of Merck’s revenue last year.

Merck’s second-largest drug by sales in 2023 was its HPV vaccine Gardasil, which saw sales increase by 29 percent to reach US$8.9 billion. On the other side of the ledger, sales of its diabetes drugs Januvia and Janumet declined by 25 percent due to increasingly available generics in Europe and declining demand in the US market.

4. Pfizer (NYSE:PFE)

Company Profile

2023 revenue: US$58.5 billion

Pfizer is a world-renowned research pharmaceutical company developing drugs in a wide range of areas, including oncology, inflammation and immunology, vaccines, internal medicine and rare diseases.

While Pfizer was eighth on this list in 2020, its revenues leaped 94 percent year-on-year in 2021, taking the company to second place. The rise was due in large part to its ‘wildly successful’ COVID-19 vaccine, which continued to drive revenues for the pharma giant in 2022, a year in which Pfizer achieved a record-breaking US$100.33 billion in revenues.

However, the pharma company has slumped from the top spot on this list to rank fourth as its revenues fell by a whopping 41 percent in 2023 as revenue from its COVID-19 products decreased.

‘It’s extremely unusual to see a Big Pharma company post a 40%-plus decline in sales, but, with Pfizer in 2023, that was indeed the situation,’ stated Fierce Pharma.

On the plus side, Pfizer’s drug sales in 2023 actually grew by 7 percent if its COVID-19 products are excluded. The publication notes that 2023 was also ‘a transition year’ for Pfizer, pointing to the US$43 billion buyout of Seagen and its suite of antibody-drug conjugate oncology drugs in December 2023.

5. AbbVie (NYSE:ABBV)

Company Profile

2023 revenue: US$54.3 billion

AbbVie is a research-driven biopharmaceutical company that develops products for chronic autoimmune diseases, neurological diseases and metabolic diseases, as well as diseases in the fields of gastroenterology, dermatology and oncology.

The company’s product Humira treats rheumatoid arthritis, chronic plaque psoriasis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis and non-infectious uveitis.

Moving forward, Abbvie will need to shift focus as Humira — one of the top-selling pharmaceuticals in history — has lost its market exclusivity in the US, and biosimilar drugs are starting to gain market share in both the US and Europe, according to Fierce Pharma.

The company is expected to lean more on its immunology offerings Skyrizi and Rinvoq, and may also tap into its war chest for more mergers and acquisitions.

6. Sanofi (NASDAQ:SNY)

Company Profile

2023 revenue: US$46.6 billion

Sanofi’s products and pipeline include treatments for diabetes and cardiovascular disease, cancers, immune system disorders, multiple sclerosis, rare diseases and rare blood disorders. Based in France, Sanofi is the world’s largest producer of vaccines thanks to its subsidiary Sanofi Pasteur.

In 2023, the company moved up two spots on this list to reach sixth place, although revenues were only up by 0.2 percent over the previous year. The company’s lead revenue generator is Dupixent. Approved by the FDA in 2017 for atopic dermatitis, the drug has been greenlit for additional uses in recent years, further fueling revenue growth.

7. AstraZeneca (NASDAQ:AZN)

Company Profile

2023 revenue: US$45.81 billion

Multinational pharma and biotech firm AstraZeneca specializes in several therapeutic areas, including oncology, cardiovascular, respiratory, central nervous system, pain control and infection.

The company has several partnerships with other pharmaceutical and biotechnology companies, including Regeneron Pharmaceuticals and Ionis Pharmaceuticals (NASDAQ:IONS).

In 2022, AstraZeneca’s revenues broke past the US$40 billion mark for the first time, and the company ranked ninth overall by revenue. Last year, the company’s revenue increased by 3.3 percent, moving AstraZeneca up two spots to seventh place.

Its oncology division was the biggest winner, posting 20 percent gains to reach US$17.1 billion sales. Lung-cancer drug Tagrisso, its largest oncology asset, brought in a total of US$5.8 billion last year, up 9 percent over 2022. The company’s immuno-oncology drugs Imfinzi and Imjudo had combined sales of US$4.2 billion, up 55 percent over the previous year.

8. Novartis (NYSE:NVS,SWX:NOVN)

Company Profile

2023 revenue: US$45.44 billion

Like Roche, Novartis is based in Basel, Switzerland. The company is focused on a wide range of disease areas, including various cancers, malaria, leprosy and sickle cell disease. Novartis is also developing a cell and gene therapy technology platform that includes adeno-associated virus-based therapy, CAR T-cell therapy and gene therapy based on CRISPR.

Revenues for Novartis grew by 7.7 percent in 2023 from US$42.21 billion in 2022, but the company dropped to the eighth spot on the list of the world’s top pharma companies by revenue. Fierce Pharma states that last year the company ‘became a pure-play innovative medicines company after spinning out its generics and biosimilar business Sandoz.’

This year’s growth was mainly attributed to its heart disease combo Entresto and multiple sclerosis injection Kesimpta, which saw sales above US$6 billion and US$2 billion, respectively.

9. Bristol-Myers Squibb Company (NYSE:BMY)

Company Profile

2023 revenue: US$45 billion

Pharmaceutical giant Bristol-Myers Squibb Company researches, develops and delivers medicines for the treatment of serious diseases, focusing on the areas of hematology, oncology, cardiology and immunology. The company launched a US$74 billion mega merger with Celgene in November 2019.

Revenues for Bristol-Myers Squibb in 2023 ticked down by 2 percent year-on-year, bumping the company from seventh to the ninth top pharma company by revenue. Much like the drugs of a few of its peers, Bristol-Myers Squibb’s sales leader, Revlimid, is slowly losing ground, leading the company to place bets on increases from its blockbuster drugs Eliquis and Opdivo.

Last year ‘marked the beginnings of a transition period as it navigates through looming patent cliffs and Inflation Reduction Act (IRA)-related threats ahead, all under a new CEO,’ said Fierce Pharma. With new IRA pricing taking effect in 2026, the company expects to see the current period of significant growth in sales of Eliquis to come to an end in 2025.

10. GSK (NYSE:GSK,LSE:GSK)

Company Profile

2023 revenue: US$38.4 billion

Last on this list of the top pharma companies by revenue, GSK has three main business divisions: pharmaceuticals, consumer healthcare and vaccines. Its pharmaceutical offerings include products for asthma, cancer, infections, diabetes and mental health. In terms of consumer healthcare, GSK has products for oral healthcare and cold sores, as well as nasal strips and nicotine patches.

Revenues for GSK in 2023 grew by 3.4 percent from US$29.32 billion in the previous year. The company’s main growth driver for the year was its shingles vaccine Shingrix, which put up 17 percent in gains.

Its newly US Food and Drug Administration approved respiratory syncytial virus (RSV) vaccine Arexvy was a new source of revenue for GSK last year. The vaccine is the world’s first RSV immunization for adults 60 years of age and older.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

In an increasingly connected world, savvy investors are looking beyond domestic borders to diversify their portfolios and capitalize on global opportunities.

Please note that this article is written with a focus on North American investors and may not fully account for the unique financial regulations, tax laws and investment practices of other regions.

What are the pros and cons of global investing?

International investing is a strategy that offers advantages and challenges. It provides access to a range of opportunities in emerging markets and high-growth sectors that may be underrepresented in North America. International stocks offer the benefit of portfolio diversification as investors can spread their stakes across different markets and currencies.

Another advantage of investing in international markets is its positive impact on the global economy. Foreign direct investment can greatly impact wealth distribution and help develop successful economies.

A flourishing global economy also benefits North American investors as economic growth in foreign markets can increase the demand for goods and services from North America.

However, investing in foreign markets also exposes investors to risks. The value of foreign investments can be affected by currency fluctuations, and return on investment may be offset by transaction costs. Market volatility arising from political and economic instability in foreign markets can also negatively impact a stock’s performance.

Moreover, international investment involves navigating different regulatory frameworks and the potential unavailability or unreliability of information about foreign enterprises and markets compared to domestic ones. This difference poses a significant challenge in making well-informed investment decisions.

“The oft-stated purpose for foreign capital deployment is to seek higher returns, improve diversification, reduce aggregate return volatility and hedge loss of purchasing power of (the) home currency,” said Stephen Johnston, a private equity manager and director of Omnigence Asset Management. “The high-level tradeoffs are political and regulatory risk and enhanced administrative and tax complexity, depending on the foreign destination.’

Johnston continued:

“Pension plans are susceptible to this reasoning as they cannot invest in higher return niche domestic opportunities given their material capital deployment needs — not so for non-institutional investors.

“It follows then that many investors could, within reason, be agnostic as to the domicile of their investment holdings, as long as those holdings suitably enhance their portfolios along the parameters above and can be implemented at the scale suitable to their individual deployment needs.”

Global investing for beginners

While global investing may sound complex it can be relatively straightforward for North Americans.

To invest in specific stocks, one option is purchasing American depositary receipts (ADRs). ADRs are issued by US banks to foreign companies, with the bank acting as a depository holding the underlying foreign shares. ADRs represent shares of a foreign company trading on a US stock exchange, denominated in US dollars.

Similarly, global depositary receipts (GDRs) represent foreign company shares and are issued by depositary banks. However, while ADRs can only be traded on US stock exchanges, GDRs can be traded on stock exchanges around the world. They are typically denominated in US dollars, euros or British pounds.

A more risk-averse option is to invest in mutual funds or ETF. Both offer diversification and professional management services, relieving investors from selecting and monitoring individual investments. They can hold a range of assets, including stocks and bonds, currencies, crypto, real estate and commodities like oil and gold.

Both mutual funds and ETFs may focus on particular sectors of the economy such as technology, healthcare, energy or automotive manufacturing. Examples of sector-specific ETFs include the Technology Select Sector SPDR Fund (ARCA:XLK), the Vanguard Health Care Index Fund ETF (ARCA:VHT) and the Energy Select Sector SPDR Fund (ARCA:XLE).

Global sector funds hold sector-specific funds from different countries, such as the iShares Global Healthcare ETF (ARCA:IXJ), which includes pharmaceutical companies from the US, Switzerland and India, three countries with strong reputations in that industry. Meanwhile, the Vanguard Information Technology Index Fund ETF (ARCA:VGT) tracks the performance of tech companies in countries known for their lucrative tech sectors.

For its part, the Fidelity International Index Fund (MUTS:FSPSX) is a mutual fund tracking the performance of the MSCI EAFE Index, which includes stocks from Europe, Australasia and the Far East.

The iShares China Large-Cap ETF (ARCA:FXI) is a country-specific fund, while the Vanguard Total International Stock Index Fund ETF (NASDAQ:VXUS) covers a broad range of international companies.

Additionally, funds may track development-based markets, such as the Vanguard FTSE Emerging Markets All Cap Index ETF (TSX:VEE), the iShares MSCI Frontier and Select EM ETF (ARCA:FM) or the T. Rowe Price Global Stock Fund (NASDAQ:PRGIX), a mutual fund that invests in developed and emerging markets around the world.

Managed volatility mutual funds employ strategies to minimize risks associated with global investing like currency fluctuations, political instability and the differences in regulatory environments. They typically hold shares in low-volatility sectors like consumer staples and utilities or multinational stocks like Johnson & Johnson.

Reuters reported on LSEG’s most recent Lipper data reading for this past July, which shows US$601 million in inflows to global volatility funds, the first net inflow in 14 months. Analysts expect more to come as investors exercise caution ahead of the November election and interest rate cuts expected in September.

Some differences between ETFs and mutual funds make them more well-suited to individual investors. Mutual funds, unlike ETFs, do not trade on stock exchanges, and their prices are calculated once a day after the markets close. ETFs can also be bought and sold in any amount, whereas mutual funds often require a minimum investment. Furthermore, mutual funds are only required to disclose their holdings once every quarter, while ETFs disclose their holdings daily. Investors generally pay less in management fees for ETFs than they do for mutual funds.

Global indexes such as the MSCI World Index (WORLD:MSCI), FTSE Global All Cap Index (INDEXFTSE:GEISAC) and the S&P Global BMI (INDEXSP:SBBMGLU) provide a benchmark for the performance of various sectors and regions in the global equity markets. Many mutual funds and ETFs aim to replicate these indexes’ performance by investing in companies and sectors represented within these indexes.

Finally, investing in multinational corporations (MNCs) is an easy way to indirectly benefit from the dynamics of international economic integration. MNCs are businesses with a significant presence in at least two countries. They often engage in foreign direct investments and have a globalized production process with revenue, operations and profits spread across different countries. This means that your investment is indirectly exposed to the economic conditions and performance of the countries it operates in. Some examples are Apple (NASDAQ:AAPL) and Toyota (NYSE:TM).

More complex global investing strategies

Direct foreign investing is another avenue that is primarily undertaken by experienced investors, high-net-worth individuals or private equity firms with a deep understanding of global markets. It’s a complex process accompanied by tax implications and other challenges that require specialized knowledge and expertise.

Establishing a brokerage account through a local firm, such as Fidelity in North America, or a foreign brokerage account in the target investment country, like Degiro in Europe, or Saxo Markets in Asia is one way to get started. Sometimes, foreign companies list their shares directly on US exchanges through initial public offerings.

Investors can also access foreign stocks through global exchanges. One of the most well-known is the MERJ Exchange, a multi-market, multi-currency platform headquartered in the Seychelles. Others include the Nordic Stock Exchange, which operates in the Nordic and Baltic countries; the Johannesburg Stock Exchange, which lists companies from various African countries as well as some international stocks; and the Euronext, a pan-European exchange that primarily operates in the European Union but includes non-member the United Kingdom.

Euronext expanded into the Asia-Pacific region in 2019 by launching Euronext FX, its foreign exchange trading platform, in Singapore. Other exchanges that facilitate trading in Asia are the Hong Kong Stock Exchange, the Tokyo Stock Exchange and the Singapore Exchange.

Another strategy is carry trades, which involves borrowing money in a low-interest-rate currency and investing in a high-interest-rate currency. The profit comes from the interest rate differential between the two currencies.

For example, until recently the Japanese yen had a very low interest rate compared to the US dollar. Investors could borrow yen, convert it to dollars and invest in US assets that yielded higher interest rates.

Carry trades can be profitable when the interest rate differential is large and the exchange rate stable. However, as the world saw on August 5 after the Bank of Japan raised interest rates — and indicated that further increases were possible — carry trades can also be risky. As the yen strengthened against the US dollar, investors sold off their higher-yielding assets and repaid their yen-denominated loans, leading to a global market selloff.

Legal considerations for global investing

Global investors must understand and comply with various securities regulations across different jurisdictions.

Some countries restrict foreign investment to protect national interests, promote domestic companies and maintain control over critical sectors of the economy. For example, China requires government approval to invest in certain sectors like telecommunications. India also imposes restrictions on foreign investment industries like defense, which is subject to government approval and is limited to a maximum foreign equity ownership of 74 percent.

Other industries are subject to special regulations that could impact operations and profitability. For example, pharmaceutical companies must navigate multiple rounds of testing and obtain approvals from various regulatory bodies, resulting in a lengthy process to bring a drug to market. While success can lead to substantial profits, these regulatory hurdles can also pose risks to potential investors.

Income tax regulations are another important area for investors to consider when participating in international markets. In the US, the Internal Revenue Service considers some foreign investment vehicles, typically foreign-based mutual funds and ETFs, as Passive Foreign Investment Companies (PFICs). The government body has implemented rules and regulations to prevent US taxpayers from deferring taxes owed from those investments. It’s crucial to know whether a stock is classified as a PFIC, because it can result in additional tax and reporting requirements.

The Canada Revenue Agency requires Canadian taxpayers to report their foreign investment income, including dividends, interest and capital gains from foreign investments. Canadian taxpayers with foreign investments may be subject to withholding taxes, a percentage of earned income from an investment that’s withheld from the investor and remitted to the tax authority where it was earned. However, Canada has tax treaties with many countries that can help mitigate withholding taxes, including Australia, Japan, Malaysia, the UK, Singapore and the US.

Many countries issue foreign tax credits to offset taxes on their foreign-source income and prevent double taxation, with specific rules and terms differing between countries. Controlled Foreign Corporation rules apply to larger stakeholders or those making direct investments in foreign companies or real estate.

Investor takeaway

Whether or not you’re a seasoned investor, understanding the dynamics of global investing, and key considerations like the risks and advantages of dabbling in international stocks, is crucial to making informed decisions and potentially reaping the rewards of a diversified portfolio.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Gold prices have soared since the start of 2024 and have set record prices in major global currencies. On August 1, the price for an ounce of gold in Australian dollars surged to AU$3,762.17, breaking the previous record of AU$3,638.01 set in April.

Recent gains have come on the back of the resumption of buying by Chinese banks, an improving US economic situation that is increasing odds of US interest rate cuts in September and ongoing geopolitical instability.

On a local level, Australia’s economy is improving as the annualized inflation rate fell to 3.5 percent in July. This marks the lowest level since March and beats June’s 3.8 percent increase. However, as inflation remains higher than the 2 to 3 percent target and July’s inflation data was slightly higher than anticipated, a rate cut from the Reserve Bank of Australia is not likely to occur in the next few months.

How have these factors affected gold stocks on the ASX? Read on to learn about the biggest gainers year-to-date.

Data for this article was retrieved on September 3, 2024, using TradingView’s stock screener, and only companies with market capitalizations greater than AU$50 million are included.

1. Larvotto Resources (ASX:LRV)

Company Profile

Year-to-date gain: 471.43 percent; market cap: AU$123.95 million; share price: AU$0.40

Larvotto Resources is a gold exploration and development company working to advance its flagship Hillgrove gold-antimony project in New South Wales, which it acquired in late 2023.

Hillgrove is currently in the pre-development stage, and Larvotto released the pre-feasibility study for the project on August 5. In the release, the company reported total resources of gold at 1.04 million ounces of gold from 7.26 million tonnes of ore with an average grade of 4.4 grams per tonne (g/t). In addition to gold, the company also reports 93,000 tonnes of antimony on site with an average grade of 1.3 percent.

The study also included a maiden ore reserve estimate, with 3.15 million tonnes of ore grading 3.2 g/t gold and 1.2 percent antimony for 320,000 ounces and 39,000 tonnes of contained metal respectively.

The company indicated a post-tax net present value of AU$157 million and an internal rate of return of 50 percent with a payback period of 2 years, contingent on prices of US$2,000 per ounce of gold and US$15,000 per tonne of antimony.

Shares in Larvotto saw significant gains following news in August that China had decided to ban antimony exports. China is the world’s largest exporter of antimony, which is used in the production of solar panels, military applications and electronics. The mineral is commonly found within gold-bearing quartz veins.

The most recent news from Hillgrove came on August 21 when the company reported that it had received the final drilling permits for the second drill program at the site and would commence 5,250 meters of drilling on August 26.

Shares in Larvotto reached a year-to-date high of AU$0.41 on August 26.

2. Australian Gold and Copper (ASX:AGC)

Company Profile

Year-to-date gain: 319.12 percent; market cap: AU$75.70 million; share price: AU$0.29

Australian Gold and Copper is an exploration company that has spent 2024 focused on advancing the Achilles gold-silver discovery at its South Cobar project in New South Wales, Australia.

The company has made several advancements at the project through its exploration programs this year, including the identification of new targets at Achilles, as reported on April 23.

A subsequent announcement on May 15 caused shares to soar when the company reported follow-up drill results from Achilles with a highlighted assay of 2.2 grams per tonne (g/t) gold over 43 metres, including 16.9 g/t gold over 5 metres.

The most recent news from Achilles came on August 5 when the company provided an exploration update on the project. In the announcement, Australian Gold and Copper reported that its recently commenced geophysical survey, which was designed to test for targets at Achilles, revealed the potential for a second zone west of Achilles that will be the target for future drilling programs.

The company also provided an update on RC drilling, saying of the 21 holes planned 14 had been completed and assays have been received for the first five, with gold, silver and base mineralization extending to the north and south and at depth. It said it would be commencing diamond core drilling in mid-August to help identify higher-grade zones at the project.

Shares of the firm reached a year-to-date high of AU$0.56 on May 22 alongside a rally in the gold price.

3. Catalyst Metals (ASX:CYL)

Company Profile

Year-to-date gain: 179.5 percent; market cap: AU$503.5 million; share price: AU$2.25

Catalyst Metals is a gold development and production company focused on its Plutonic mine in Western Australia and Henty mine in Tasmania.

The company acquired Plutonic as part of a takeover of Vango Mining in 2023. On March 28, the company announced it had repaid the first tranche of an AU$12.1 million convertible note that it inherited as part of the purchase.

Since the takeover, Catalyst has been working to increase production at the mine, and the company announced in its March quarterly report that performance had improved. Production for the quarter reached 21,252 ounces of gold, a slight increase over the previous quarter despite equipment breakdowns.

In the company’s fiscal year-end update released on July 10, the company said it continued to make improvements at Plutonic, with production at the mine year reaching 85,000 ounces under its ownership versus only 60,000 ounces in the previous year, which was prior to its acquisition.

As for its Henty mine, Catalyst said Henty achieved record quarterly production of 6,926 ounces in its fiscal Q4 and produced 24,982 during the year. According to the company, the mine is on its way to annual production of 30,000.

Catalyst also said it had reduced debt from AU$36 million to AU$8 million.

The most recent announcement from Catalyst came on August 29, when it released its in-depth year-end results. During the period, the company achieved its first profit, with a net after-tax profit of AU$23.56 million versus an after-tax loss of AU$15.63 million in the previous year.

Shares in Catalyst reached a year-to-date high of AU$2.28 on August 29.

4. WIA Gold (ASX:WIA)

Company Profile

Year-to-date gain: 173.81 percent; market cap: AU$125.50 million; share price: AU$0.12

WIA Gold is an exploration company focused on developing projects in Africa. The company’s primary goal is to advance the Kokoseb deposit at its Damaran gold project.

Kokoseb is located on WIA’s Okombahe exploration licence, which consists of 12 tenements across a 2,700 square kilometre area within the Damaran Belt in Northwest Namibia. WIA Gold holds an 80 percent stake in the exploration licence, with the remaining 20 percent being held by Namibian state-owned mining company Epangelo.

On April 16, the company released an updated resource estimate for Kokoseb, reporting 2.12 million ounces of gold from 66 million tonnes at 1 g/t gold with a cut off of 0.5 g/t gold.

The company reported drill results from the project on August 20 that identified high-grade mineralization below the current resource as well as new mineralization in the Eastern zone. WIA reported a highlighted intercept from the new area grading 4.95 g/t gold over 4 metres.

WIA Gold also owns the early stage Bouafle project, which is located in Côte d’Ivoire and has been granted two exploration permits, with a third under application. On May 27, WIA reported that it had commenced reverse-circulation drilling at the site with the intention to test 10 previously identified trends.

In a recent update on September 2, the company reported results from the first phase of reconnaissance drilling at Bouafle. Highlighted assays from the 5,682 metre drill campaign included 4.54 g/t over 10 meters and 87.43 g/t over 4 meters. The company plans to follow it with a second phase of 2,000 metres in October.

Shares in WIA Gold reached a year-to-date high of AU$0.125 on May 21 alongside a surging gold price.

5. Spartan Resources (ASX:SPR)

Press ReleasesCompany Profile

Year-to-date gain: 165.15 percent; market cap: AU$1.58 billion; share price: AU$1.37

Spartan Resources is a gold exploration and development company whose core assets are located in Western Australia. Its flagship operation, the Dalgaranga gold mine, produced 71,153 ounces of the metal in 2022 before being placed on care and maintenance as low grades reduced the asset’s viability.

Spartan has since turned its focus to increasing grades and expanding Dalgaranga’s resource estimate. It has largely focused on the Never Never deposit, which it discovered in 2022.

Exploration at the site has continued in 2024, and on April 18 Spartan reported the discovery of a new lode, dubbed the Pepper prospect, situated 90 metres south of the main Never Never deposit. The company said Pepper has similar mineralization and grades to Never Never, with one assay showing 15.86 g/t gold over 17.52 metres, including 27.89 g/t gold over 9.22 metres.

Using data from exploration efforts at Pepper, Spartan released an updated mineral resource estimate for Dalgaranga on July 23 showing a contained resource of 2.48 million ounces of gold from 16.1 million tonnes of ore with an average grade of 4.79 g/t gold.

It was up significantly from Spartan’s December 2023 resource estimate, which came in at 1.7 million ounces, including 952,000 ounces at Never Never. The increase is attributable to the additional 438,100 ounces of gold from Pepper and an increase at Never Never to 1.49 million ounces.

In an exploration update on August 28, Spartan reported that a drill hole at Pepper contained the highest-grade interval to date at Dalgaranga. Drilling intercepted 39.15 g/t gold over 27.01 metres, including an intersection of 121.35 g/t over 5.11 metres.

Shares of Spartan reached a year-to-date high of AU$1.455 on August 29.

FAQs for ASX gold stocks

How to invest in gold on the ASX?

As Australia is a top gold-mining jurisdiction and the country’s government is supportive of mining, there are plenty of options for investing in gold on the ASX. Between gold miners operating major projects and gold explorers hunting for the next significant gold discovery, investors can choose what kind of company matches their risk appetite and portfolio.

When looking for a gold company to invest in, be sure to do your due diligence and learn about the company’s key characteristics, including its leadership team, its finances and the geology of its projects.

How to buy gold on the ASX?

Once you’ve selected a company or multiple companies to invest in, you can buy gold stocks using trading apps with access to ASX stocks, or you can get the help of a stock broker.

How to buy gold ETFs on the ASX?

For investors who prefer broader exposure to a sector, exchange-traded funds (ETFs) are a good option, and the ASX is home to multiple gold-focused ETFs. Because they are traded on exchanges like stocks, you can buy ETFs using the same methods described above. ASX-listed gold ETFs to consider include:

Securities Disclosure: I, Dean Belder, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

John Feneck, portfolio manager and consultant at Feneck Consulting, shared his latest thoughts on the gold sector, saying that with the yellow metal’s price reaching all-time highs now is a good time to buy gold stocks.

‘Gold has now trended higher for months. Last year it was forming a base at US$1,900 (per ounce), this year it’s forming a base at US$2,300 to US$2,400. And this is for weeks and weeks and weeks,’ he explained.

‘When you see this kind of basing pattern in any chart it’s called consolidation — it’s a really good chart pattern to look for where you’re building a base that you can build off of usually — not the other way where it crashes and burns.’

Feneck gave overviews of a variety of small-cap resource stocks he’s watching. Precious metals stocks on his radar at the moment include Guanajuato Silver (TSXV:GSVR,OTCQX:GSVRF) and Silver X Mining (TSXV:AGX,OTCQB:AGXPF).

Moving over to copper, he mentioned Inflection Resources (CSE:AUCU,OTCQB:AUCUF), Vox Royalty (TSX:VOXR,NASDAQ:VOXR), Alta Copper (TSX:ATCU,OTCQX:ATCUF) and Denarius Metals (OTCQX:DNRSF).

‘Special situation’ companies with different ideas or exposure to lesser-known sectors are also of interest to Feneck. Examples include Millennial Potash (TSXV:MLP,OTCQB:MLPNF) and Angkor Resources (TSXV:ANK,OTCQB:ANKOF).

Watch the interview above for more from Feneck on the resource sector and the companies he’s eyeing.

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Indigenous community leader publicly endorses Laguna Verde project at key mining seminar in Santiago, Chile

CleanTech Lithium PLC (AIM:CTL)(Frankfurt:T2N)(OTCQX:CTLHF), an exploration and development company advancing sustainable lithium projects in Chile, participated in the Centre for Copper and Mining Studies (‘CESCO’) seminar in Santiago, a prominent annual seminar for the mining sector in Chile, and received public support from the local indigenous community for its Laguna Verde project. Executive Chairman and Interim CEO, Steve Kesler, presented and reinforced the Company is ready to begin project construction by 2026 upon the granting of a Special Lithium Operating Contract (‘CEOL’) by the Chilean Government

Highlights:

CESCO seminar brought together key industry stakeholders including government and local community representatives to discuss the development of the lithium sector in Chile

Ercilia Araya, President of the Colla Pai-Ote indigenous community expressed support for lithium project development depending on companies building solid community relationships and agreements, as achieved by CTL, and advocating for such projects to move forward.

Industry experts discussed the main challenges facing the sector and how to advance projects faster in line with the National Lithium Strategy, with implementing sustainable extraction technologies such as Direct Lithium Extraction being critical to that.

CTL has a co-signed agreement with the nearby local communities which will initially focus on the Laguna Verde project and aligns with the priorities set by the Chilean Government to advance the objectives of the National Lithium Strategy

Steve Kesler, Executive Chairman and Interim Chief Executive Officer, CleanTech Lithium PLC, said:

‘We are very well placed to be one of the projects that the Government aims to have operational by 2026. We believe the Laguna Verde project is the best-positioned new lithium project to commence operations in Chile within the earliest timeframe. We highly value the support of the indigenous community which we think provides a rare and valuable partnership in facilitating mutually beneficial project development.’

Ercilia Araya, President of the Colla Pai-Ote indigenous community, said:

‘We want the State to respect us in our territories and recognise our right to determine to whom the CEOLs are granted through proper indigenous consultations. It is a matter of dignity. I have a dream for the Atacama region. When CleanTech arrived, they explained how they would carry out the process, building together with us the information collection for submission of the EIA. That is our dream. The dream of being able to participate, to be consulted.’

Image 1: Ercilia Araya, President Pai-Ote Colla Community speaking at the CESCO Seminar in Santiago, Chile

Image 2: Marcela Sepúlveda, Community Relations Manager CleanTech Lithium, Cristián Quinzio, Quinzio Abogados, Alina Bendersky, Partner Bofil Mir, Ercilia Araya, President Pai-Ote Colla Community and Juan Ignacio Guzmán, Executive Director, GEM

Image 3: Steve Kesler, Executive Chairman and Interim CEO, presenting at the CESCO Seminar in Santiago, Chile

The seminar, organised by CESCO, brought together industry spokespeople to provide a comprehensive view of the current situation of the lithium industry in Chile, considering the progress of the National Lithium Strategy.

Juan Esteban Fuentes, Associate Director at Benchmark Minerals, attended and further commented: ‘From 2030, the current surplus [of lithium] is expected to diminish, requiring a significant number of projects to double production over the next 10 years globally (to around 2.6 million tonnes), which implies the incorporation of 70 to 80 more operations and US$188 billion in capital by 2040.’

Arlene Ebensperger, advisor to the Ministry of Mining, also highlighted the need to harmonise the role of indigenous communities with the development of the industry through governance models which builds a shared vision and agreed objectives.

CleanTech Lithium co-signed an agreement with the local indigenous communities in 2023. The alliance will ensure that the extraction processes conducted in the region by the Company comply with the highest international standards, including a process of early consultation with the communities to see their direct participation by providing data for the environmental baselines required for the Environmental Impact Assessment (EIA).

For further information contact:

CleanTech Lithium PLC

Steve Kesler/Gordon Stein/Nick Baxter

Jersey office: +44 (0) 1534 668 321

Chile office: +562-32239222

Or via Celicourt

Celicourt Communications

Felicity Winkles/Philip Dennis/Ali AlQahtani

+44 (0) 20 7770 6424

cleantech@celicourt.uk

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish/Asia Szusciak

+44 (0) 20 7628 3396

Fox-Davies Capital Limited (Joint Broker)

Daniel Fox-Davies

+44 (0) 20 3884 8450

daniel@fox-davies.com

Canaccord Genuity (Joint Broker)

James Asensio

+44 (0) 20 7523 4680

Beaumont Cornish Limited (‘Beaumont Cornish’) is the Company’s Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish’s responsibilities as the Company’s Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

Notes

CleanTech Lithium (AIM:CTL, Frankfurt:T2N, OTCQX:CTLHF) is an exploration and development company advancing lithium projects in Chile for the clean energy transition. Committed to net-zero, CleanTech Lithium’s mission is to become a new supplier of battery grade lithium using Direct Lithium Extraction technology powered by renewable energy.

CleanTech Lithium has two key lithium projects in Chile, Laguna Verde and Viento Andino, and exploration stage projects in Llamara and Arenas Blancas (Salar de Atacama), located in the lithium triangle, a leading centre for battery grade lithium production. The two most advanced projects: Laguna Verde and Viento Andino are situated within basins controlled by the Company, which affords significant potential development and operational advantages. All four projects have good access to existing infrastructure.

CleanTech Lithium is committed to utilising Direct Lithium Extraction with reinjection of spent brine resulting in no aquifer depletion. Direct Lithium Extraction is a transformative technology which removes lithium from brine with higher recoveries, short development lead times and no extensive evaporation pond construction. www.ctlithium.com

**ENDS**

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE:CleanTech Lithium plc

View the original press release on accesswire.com

News Provided by ACCESSWIRE via QuoteMedia

This post appeared first on investingnews.com

CleanTech Lithium PLC (AIM: CTL, Frankfurt:T2N, OTCQX:CTLHF), an exploration and development company advancing sustainable lithium projects in Chile, participated in the Centre for Copper and Mining Studies (‘CESCO’) seminar in Santiago, a prominent annual seminar for the mining sector in Chile, and received public support from the local indigenous community for its Laguna Verde project. Executive Chairman and Interim CEO, Steve Kesler, presented and reinforced the Company is ready to begin project construction by 2026 upon the granting of a Special Lithium Operating Contract (‘CEOL’) by the Chilean Government.

Highlights:

CESCO seminar brought together key industry stakeholders including government and local community representatives to discuss the development of the lithium sector in ChileErcilia Araya, President of the Colla Pai-Ote indigenous community expressed support for lithium project development depending on companies building solid community relationships and agreements, as achieved by CTL, and advocating for such projects to move forward.Industry experts discussed the main challenges facing the sector and how to advance projects faster in line with the National Lithium Strategy, with implementing sustainable extraction technologies such as Direct Lithium Extraction being critical to that.CTL has a co-signed agreement with the nearby local communities which will initially focus on the Laguna Verde project and aligns with the priorities set by the Chilean Government to advance the objectives of the National Lithium Strategy

Steve Kesler, Executive Chairman and Interim Chief Executive Officer, CleanTech Lithium PLC, said:

‘We are very well placed to be one of the projects that the Government aims to have operational by 2026. We believe the Laguna Verde project is the best-positioned new lithium project to commence operations in Chile within the earliest timeframe. We highly value the support of the indigenous community which we think provides a rare and valuable partnership in facilitating mutually beneficial project development.’

Ercilia Araya, President of the Colla Pai-Ote indigenous community, said:

We want the State to respect us in our territories and recognise our right to determine to whom the CEOLs are granted through proper indigenous consultations. It is a matter of dignity. I have a dream for the Atacama region. When CleanTech arrived, they explained how they would carry out the process, building together with us the information collection for submission of the EIA. That is our dream. The dream of being able to participate, to be consulted.’

Image 1: Ercilia Araya, President Pai-Ote Colla Community speaking at the CESCO Seminar in Santiago, Chile

Image 2: Marcela Sepúlveda, Community Relations Manager CleanTech Lithium, Cristián Quinzio, Quinzio Abogados, Alina Bendersky, Partner Bofil Mir, Ercilia Araya, President Pai-Ote Colla Community and Juan Ignacio Guzmán, Executive Director, GEM

Image 3: Steve Kesler, Executive Chairman and Interim CEO, presenting at the CESCO Seminar in Santiago, Chile

The seminar, organised by CESCO, brought together industry spokespeople to provide a comprehensive view of the current situation of the lithium industry in Chile, considering the progress of the National Lithium Strategy.

Juan Esteban Fuentes, Associate Director at Benchmark Minerals, attended and further commented: ‘From 2030, the current surplus [of lithium] is expected to diminish, requiring a significant number of projects to double production over the next 10 years globally (to around 2.6 million tonnes), which implies the incorporation of 70 to 80 more operations and US$188 billion in capital by 2040.’

Arlene Ebensperger, advisor to the Ministry of Mining, also highlighted the need to harmonise the role of indigenous communities with the development of the industry through governance models which builds a shared vision and agreed objectives.

CleanTech Lithium co-signed an agreement with the local indigenous communities in 2023. The alliance will ensure that the extraction processes conducted in the region by the Company comply with the highest international standards, including a process of early consultation with the communities to see their direct participation by providing data for the environmental baselines required for the Environmental Impact Assessment (EIA).

For further information contact:

CleanTech Lithium PLC

Steve Kesler/Gordon Stein/Nick Baxter

Jersey office: +44 (0) 1534 668 321

Chile office: +562-32239222

Or via Celicourt

Celicourt Communications

Felicity Winkles/Philip Dennis/Ali AlQahtani

+44 (0) 20 7770 6424

cleantech@celicourt.uk

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish/Asia Szusciak

+44 (0) 20 7628 3396

Fox-Davies Capital Limited (Joint Broker)

Daniel Fox-Davies

+44 (0) 20 3884 8450

daniel@fox-davies.com

Canaccord Genuity (Joint Broker)

James Asensio

+44 (0) 20 7523 4680

Beaumont Cornish Limited (‘Beaumont Cornish’) is the Company’s Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish’s responsibilities as the Company’s Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

Notes

CleanTech Lithium (AIM:CTL, Frankfurt:T2N, OTCQX:CTLHF) is an exploration and development company advancing lithium projects in Chile for the clean energy transition. Committed to net-zero, CleanTech Lithium’s mission is to become a new supplier of battery grade lithium using Direct Lithium Extraction technology powered by renewable energy.

CleanTech Lithium has two key lithium projects in Chile, Laguna Verde and Viento Andino, and exploration stage projects in Llamara and Arenas Blancas (Salar de Atacama), located in the lithium triangle, a leading centre for battery grade lithium production. The two most advanced projects: Laguna Verde and Viento Andino are situated within basins controlled by the Company, which affords significant potential development and operational advantages. All four projects have good access to existing infrastructure.

CleanTech Lithium is committed to utilising Direct Lithium Extraction with reinjection of spent brine resulting in no aquifer depletion. Direct Lithium Extraction is a transformative technology which removes lithium from brine with higher recoveries, short development lead times and no extensive evaporation pond construction.www.ctlithium.com


Source

Click here to connect with CleanTech Lithium PLC (AIM:CTL, OTCQX:CTLHF, Frankfurt:T2N), to receive an Investor Presentation

This post appeared first on investingnews.com

The battle for Rupert Murdoch’s global media kingdom is headed to the biggest little city in the world.

Murdoch, the 93-year-old billionaire press baron, reportedly wants to alter the terms of an irrevocable trust so that his eldest son, Lachlan, inherits his throne and keeps control of prized assets such as Fox News and The Wall Street Journal. But three of the mogul’s other children — James, Elisabeth and Prudence — are pushing back, insisting that all four siblings continue to receive equal voting shares.

The family feud goes before a judge at the Washoe County Courthouse in Reno, Nevada, next week, but the proceedings and case filings are shrouded in secrecy. Alicia L. Lerud, an administrator at the Second Judicial District Court, confirmed to NBC News that the Murdoch matter is under seal and “confidential pursuant to court order.” (Reno probate court frequently deals with family trusts and estates.)

In late July, however, The New York Times published an article based on a copy of a sealed court document laying out some of the case’s key issues. NBC News has not independently seen the document or confirmed its authenticity. Gary A. Bornstein, the litigator representing the three siblings, and Adam Streisand, the lawyer representing their father, did not respond to requests for comment from NBC News.

Murdoch is one of the most powerful and influential media titans of the modern age. He built a small Australian newspaper business into a mighty collection of broadcast and cable television properties. The crown jewel remains Fox News, a pillar of the American conservative movement and home to high-profile opinion hosts who staunchly defend former President Donald Trump.

The palace intrigue inside the Murdoch family has often lent itself to breathless public fascination, inspiring the HBO series “Succession” and behind-the-scenes books.

The family is divided partly by differences in political opinion — and how those beliefs could shape the future of its sprawling media empire. Lachlan Murdoch, who took over as chairman of Fox Corp. and News Corp. last September, tends to be more aligned with his father’s conservative worldview. 

James Murdoch, Elisabeth Murdoch and Prudence Murdoch are believed to be more politically moderate. James Murdoch has endorsed Vice President Kamala Harris’ presidential candidacy, and Federal Election Commission records show he has donated hundreds of thousands of dollars to Democratic congressional candidates and Democratic state parties.

The Times, citing the court document, reported that the elder Murdoch believes the “lack of consensus” among the four children “would impact the strategic direction at both companies including a potential reorientation of editorial policy and content.” The mogul filed a petition to amend the trust as he seeks to “consolidate decision-making power in Lachlan’s hands and give him permanent, exclusive control.”

Nevada’s probate commissioner found in June that Murdoch could change the irrevocable trust if the wealthy patriarch was able to demonstrate he was acting in good faith, for the sole benefit of his heirs, according to a copy of the 48-page decision cited by The Times. (Murdoch has two other children, both in their early 20s, from his third of five marriages.)

In the event Lachlan Murdoch cements control of the corporate properties, Fox News’ opinion programming will likely continue to be solidly conservative and a major influence on Republican politics. 

Fox News has been tightly linked with Trump in recent years. The company was sued by Dominion Voting Systems for airing baseless claims of vote-rigging after the 2020 election. The two sides ultimately settled for $787.5 million, heading off a jury trial.

“Rupert Murdoch has always been good at harmonizing his business interests and his ideological goals, and he seems to view Lachlan as the one sibling who can thread that needle,” said Reece Peck, an associate professor of media culture at the City University of New York-College of Staten Island and the author of “Fox Populism: Branding Conservatism as Working Class.”

This post appeared first on NBC NEWS

Discount home goods retailer Big Lots filed for bankruptcy protection on Monday after high interest rates and a sluggish housing market slowed demand for its low-priced furniture and decor. 

As part of its Chapter 11 filing, Big Lots agreed to sell its business to private equity firm Nexus Capital Management for about $760 million, consisting of $2.5 million in cash plus its remaining debt and liabilities, court records show. 

The company, which runs more than 1,300 stores across 48 states, is one of the country’s largest closeout retailers and specializes in offering bargain-basement pricing on all things home. It brought in about $4.7 billion in revenue in fiscal 2023, but sales have consistently fallen after pandemic-era demand for home furnishings dropped.

In a press release and court filings, Big Lots said it will operate its business normally but has started the process of closing nearly 300 stores so it can fix its balance sheet and reduce costs.

“The actions we are taking today will enable us to move forward with new owners who believe in our business and provide financial stability, while we optimize our operational footprint, accelerate improvement in our performance, and deliver on our promise to be the leader in extreme value,” CEO Bruce Thorn said in a news release. “As we move through this process, we remain committed to offering extreme bargains, enabling easy shopping in our stores and online, and providing an outstanding customer experience.” 

Evan Glucoft, managing director at Nexus, said the firm is “confident” that Big Lots’ “greatest days are ahead.” 

“We are excited to have the opportunity to partner with Big Lots and help return this iconic brand to its status as America’s leading extreme value retailer,” said Glucoft. 

Big Lots has been teetering near the edge for months after high interest rates and a sluggish housing market slowed consumer demand for new furniture, decor and other home supplies. While discount retailers tend to do well in rough economic cycles, Big Lots primarily caters to lower- and middle-income consumers, who have curbed discretionary spending at a higher rate than their more affluent counterparts. 

“The company has been adversely affected by recent macroeconomic factors such as high inflation and interest rates that are beyond its control,” Big Lots said in a news release. “The prevailing economic trends have been particularly challenging to Big Lots, as its core customers curbed their discretionary spending on the home and seasonal product categories that represent a significant portion of the company’s revenue.” 

Beyond macroeconomic conditions, Big Lots also operates in a highly competitive space and has struggled to differentiate itself from other discounters that offer home goods or specialize in the category, such as Wayfair, Walmart and TJX Cos.′ Home Goods.

“Big Lots is not always good value for money. Many of the items it sells are not high end and are not drastically expensive, but equivalents can often be found much cheaper at other stores, including Walmart,” Neil Saunders, managing director of GlobalData, said in a note.

“The other issue [is] the assortment is very jumbled and muddled, which is partly a function of the way the business operates,” Saunders added. “However, there is far too much choice and not nearly enough treasure for consumers to be enticed by. This creates an unsatisfactory shopping experience, especially compared to other players operating in the discount space, such as off-price retailers.”

As part of the bankruptcy process, Big Lots will hold a court-supervised auction for its business. It could go to a different buyer if they make a bid that’s higher than Nexus’ offer. 

It’s working with law firm Davis Polk & Wardwell, investment bank Guggenheim Securities and advisory firm AlixPartners. A&G Real Estate Partners has been tapped as Big Lots’ real estate advisor, while Nexus will be represented by law firm Kirkland & Ellis.

This post appeared first on NBC NEWS